Diabetes & Endocrinology
Latest news
532 articles · 20 / page
Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial
A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentia
SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis
A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stag
Managing Obesity as a Chronic Disease: The 2026 WHO Guidelines on GLP-1 Therapies
The World Health Organization (WHO) has released its landmark 2026 guidelines on GLP-1 therapies for obesity, reclassifying the condition as a chronic, relapsing disease requiring long-term pharmacological and behavioral management while em
New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window
A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.
Precision Prognostics in Sepsis: How Stress Hyperglycemia and Glucose Variability Define Mortality Risk Across Metabolic Profiles
This study reveals that combining stress hyperglycemia ratio and glucose variability significantly improves mortality prediction in sepsis, with risk patterns varying significantly based on a patient’s baseline metabolic status (Normal, Pre
Signaling-Biased Dual GLP-1/GIP Agonist CT-388 Achieves Remarkable 8% Weight Loss in Just Four Weeks
A Phase 1 study of CT-388, a novel signaling-biased dual GLP-1/GIP receptor agonist, demonstrated up to 8% body weight reduction in 28 days with a safety profile consistent with existing incretin therapies, signaling a potential shift in me
Liraglutide and Alzheimer’s Disease: Can GLP-1 Agonists Bridge the Metabolic-Cognitive Gap?
The Phase 2b ELAD trial investigated liraglutide’s efficacy in mild-to-moderate Alzheimer’s disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1 agonists in
Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control
This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic
Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems
A randomized trial reveals that while automated decision support systems show marginal overall glycemic benefits in type 1 diabetes, personalized informative feedback significantly aids users with lower baseline knowledge. Success depends h
Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes
A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvement
GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients
This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra
Predicting the Clock: Machine Learning Refines Insulin Timing in Gestational Diabetes Management
A secondary analysis of the EMERGE trial reveals that Random Survival Forest models utilizing early glycemic data can accurately predict the time to insulin initiation in women with gestational diabetes, offering a roadmap for personalized
The Sweet Tooth Trial: Evidence Challenges the Assumption That Lowering Exposure Reduces Sweet Taste Liking
A 6-month randomized controlled trial reveals that varying dietary sweet taste exposure does not alter sweet taste liking, energy intake, or body weight, questioning the efficacy of public health recommendations to reduce sweet exposure for
Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes
A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.
GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a
Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes
A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.
Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight
The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing swee
Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes
A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible
Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study
This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate
Browse by specialty
Open language-specific specialty feeds and department pages.